COChristina Orsmark-Pietras

Christina Orsmark-Pietras

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Christina Orsmark-Pietras has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Whole-genome sequencing enables improved AML diagnostics and refines assessment of TP53 allelic state and complex karyotype

    by Petr Stanek, Christina Orsmark-Pietras, Rasmus Henningsson, Marianne Rissler, Niklas Landberg, Helena Ågerstam, Anna Staffas, Linda Fogelstrand, Lars Palmqvist, Gisela Barbany, et al.

    Accurate genetic characterization is central to modern acute myeloid leukemia (AML) diagnostics, yet current standard-of-care (SoC) testing relies on multiple complementary assays. We compared paired tumor-normal whole-genome sequencing (WGS) with SoC diagnostics in a population-based cohort of 109 adult AML patients, assessing variant detection, disease classification according to ICC 2022 and WHO 2022, and risk stratification according to ELN 2022. WGS showed high concordance with SoC across variant classes. When considering all reported SoC variants together with high-confidence WGS variants as true positives, WGS showed equal to higher sensitivity than SoC for single-nucleotide variants and small insertions/deletions (97% vs 92%), structural variants (SVs; 100% vs 87%), and copy-number alterations (CNAs; 88.5% both). WGS identified clinically important lesions missed by SoC in 16 cases (15%), including FLT3-ITDs and KMT2A, NUP98 and MECOM rearrangements. Classification and risk assignments were 95-96% concordant, with WGS-driven reclassifications in 4-5% of cases, primarily through detection of cryptic SVs and myelodysplasia-related lesions. Integrated analysis of genomic alterations, including copy-neutral loss-of-heterozygosity, refined TP53 allelic state assessment and demonstrated increased genomic complexity in AML with biallelic TP53 alterations. We developed a supervised machine-learning model for complex karyotype (CK) probability, based on WGS-derived copy-number and SV burden, enabling automated identification of CK cases from WGS data. Collectively, these results support paired tumor-normal WGS as a single comprehensive assay well suited for AML diagnostics according to current classification and risk-stratification systems, while refining assessment of TP53 allelic state and karyotypic complexity.

  • Open Access

    The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes

    by Henrik Lilljebjörn, Pablo Peña-Martínez, Hanna Thorsson, Rasmus Henningsson, Marianne Rissler, Niklas Landberg, Noelia Puente-Moncada, Sofia von Palffy, Vendela Rissler, Petr Stanek, et al.

    Acute myeloid leukemia is a genetically and cellularly heterogeneous disease. We characterize 120 AMLs using genomic and transcriptomic analyses, including single-cell RNA sequencing. Our results reveal an extensive cellular heterogeneity that distorts the bulk transcriptomic profiles. Selective examination of the transcriptional signatures of >90,000 immature AML cells identifies four main clusters, thereby extending current genomic classification of AML. Notably, NPM1 -mutated AML can be stratified into two clinically relevant classes, with NPM1 class I associated with downregulation of MHC class II and excellent survival following hematopoietic stem cell transplantation. NPM1 class II is instead associated with resistance to allogeneic T cells in an ex vivo co-culture assay, and importantly, dismal survival following hematopoietic stem cell transplantation. These findings provide insights into the cellular state space of AML, define diagnostic entities, and highlight potential therapeutic intervention points.


  • Open Access

    Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia

    by Carl Sandén, Niklas Landberg, Pablo Peña-Martínez, Hanna Thorsson, Shruti Daga, Noelia Puente-Moncada, Maria Rodriguez-Zabala, Sofia von Palffy, Marianne Rissler, Vladimir Lazarevic, et al.

    Immunotherapy has shown limited success in acute myeloid leukemia (AML), indicating an incomplete understanding of the underlying immunoregulatory mechanisms. Here we identify an immune evasion mechanism present in 60% of AML cases, wherein primitive AML cells aberrantly express the lymphoid surface protein SLAMF6 (signaling lymphocyte activation molecule family member 6). Knockout of SLAMF6 in AML cells enables T cell activation and highly efficient killing of leukemia cells in coculture systems, demonstrating that SLAMF6 protects AML cells from recognition and elimination by the immune system in a mode analogous to the programmed cell death protein–ligand (PDL1/PD1) axis. Targeting SLAMF6 with an antibody against the SLAMF6 dimerization site inhibits the SLAMF6–SLAMF6 interaction and induces T cell activation and killing of AML cells both in vitro and in humanized in vivo models. In conclusion, we show that aberrant expression of SLAMF6 is a common and targetable immune escape mechanism that could pave the way for immunotherapy in AML.


  • Open Access

    TLE3 Is a Novel Fusion Partner of JAK2 in Myeloid/Lymphoid Neoplasm With Eosinophilia Responding to JAK2 Inhibition

    by Vladimir Lazarevic, Henrik Lilljebjörn, Linda Olsson‐Arvidsson, Christina Orsmark‐Pietras, Helena Ågerstam

    Chromosomal rearrangements involving Janus kinase 2 (JAK2) are rare but recurrent findings in lymphoid or myeloid neoplasia. Detection of JAK2 fusion genes is important as patients with aberrantly activated JAK2 may benefit from treatment with tyrosine kinase inhibitors such as ruxolitinib. Here, we report a novel fusion gene between the transcriptional co‐repressor‐encoding gene transducin‐like enhancer of split 3 (TLE3) and JAK2 in a patient initially diagnosed with chronic eosinophilic leukemia with additional mutations in PTPN11 and NRAS. The patient was successfully treated with the JAK2 inhibitor ruxolitinib for 8 months before additional somatic mutations were acquired and the disease progressed into an acute lymphoblastic T‐cell leukemia/lymphoma. The present case shows similarities to previously reported cases with PCM1::JAK2 and BCR::JAK2 with regard to disease phenotype and response to ruxolitinib, and importantly, provides an example that also patients harboring other JAK2 fusion genes may benefit from treatment with JAK2 inhibitors.

  • Open Access

    Precision Diagnostics in Myeloid Malignancies: Development and Validation of a National Capture‐Based Gene Panel

    by Christina Orsmark‐Pietras, Anna Lyander, Claes Ladenvall, Björn Hallström, Anna Staffas, Hero Awier, Aleksandra Krstic, Panagiotis Baliakas, Gisela Barbany, Cecilia Brunhoff Håkansson, et al.

    Gene panel sequencing has become a common diagnostic tool for detecting somatically acquired mutations in myeloid neoplasms. However, many panels have restricted content, provide insufficient sensitivity levels, or lack clinically validated workflows. We here describe the development and validation of the Genomic Medicine Sweden myeloid gene panel (GMS‐MGP), a capture‐based 191 gene panel including mandatory genes in contemporary guidelines as well as emerging candidates. The GMS‐MGP displayed uniform coverage across all targets, including recognized difficult GC‐rich areas. The validation of 117 previously described somatic variants showed a 100% concordance with a limit‐of‐detection of a 0.5% variant allele frequency (VAF), achieved by utilizing error correction and filtering against a panel‐of‐normals. A national interlaboratory comparison investigating 56 somatic variants demonstrated highly concordant results in both detection rate and reported VAFs. In addition, prospective analysis of 323 patients analyzed with the GMS‐MGP as part of standard‐of‐care identified clinically significant genes as well as recurrent mutations in less well‐studied genes. In conclusion, the GMS‐MGP workflow supports sensitive detection of all clinically relevant genes, facilitates novel findings, and is, based on the capture‐based design, easy to update once new guidelines become available. The GMS‐MGP provides an important step toward nationally harmonized precision diagnostics of myeloid malignancies.


  • Open Access

    Single-Cell Genomics Details the Maturation Block in BCP-ALL and Identifies Therapeutic Vulnerabilities in DUX4-Rearranged Cases

    by Hanna Thorsson, Rasmus Henningsson, Noelia Puente-Moncada, Ludvig Sjöström, Helena Ågerstam, Pablo Enrique Peña-Martínez, Carl Sandén, Marianne Rissler, Anders Castor, Hanne Vibeke Marquart, et al.

    B cell progenitor acute lymphoblastic leukemia (BCP-ALL) is the most common childhood malignancy. It is initiated by multiple genetic alterations, causing a maturation arrest and accumulation of abnormal progenitor B cells. Current treatment protocols with chemotherapy have led to favorable outcomes, but are associated with significant toxicity and risk of side effects, highlighting the necessity for highly effective, less toxic, targeted drugs that also show efficacy in children experiencing relapse. We have used multimodal single-cell sequencing to delineate the transcriptional, epigenetic, and immunophenotypic characteristics of 23 childhood BCP-ALLs, including the BCR::ABL1-positive, ETV6::RUNX1-positive, high hyperdiploid, and recently discovered DUX4-rearranged subtypes. In total, 188,546 single cells derived from 23 BCP-ALLs and 9 normal bone marrow samples were profiled using the 10X Genomics platform. Cellranger multi and atac count (10X Genomics) were used to generate read count matrices. Further analysis was performed using Seurat and Signac. The in-house developed program SingleCellProjections was used to create a normal bone marrow reference graph onto which the BCP-ALL data was projected. Projection of the ALL cells along the normal B cell differentiation axis, revealed a diversity in the maturation block between the different BCP-ALL subtypes. Whereas the BCR::ABL1-, ETV6::RUNX1-positive and high hyperdiploidy cells mainly showed similarities to normal pro-B cells, the DUX4-rearranged ALL cells also displayed a transcriptional signature resembling mature B cells. In addition, the blast population in DUX4-rearranged ALLs showed multilineage priming toward non-hematopoietic cells, myeloid and T cell lineages, but also an activation of PI3K/AKT signaling that sensitized the cells to PI3K inhibition. Finally, we show that chimeric antigen receptor T cell therapy targeting the upregulated myeloid receptor CD371 (CLL-1), effectively eliminates DUX4-rearranged ALL cells. Our results provide a detailed characterization of BCP-ALL at the single-cell level and reveal therapeutic vulnerabilities in the DUX4-rearranged subtype with important implications for the understanding of ALL biology and new therapeutic strategies.

  • Open Access

    Clinical and genomic characterization of patients diagnosed with the provisional entity acute myeloid leukemia with BCR‐ABL1, a Swedish population‐based study

    by Christina Orsmark‐Pietras, Niklas Landberg, Fryderyk Lorenz, Bertil Uggla, Martin Höglund, Sören Lehmann, Åsa Derolf, Stefan Deneberg, Petar Antunovic, Jörg Cammenga, et al.

    Acute myeloid leukemia (AML) with t(9;22)(q34;q11), also known as AML with BCR‐ABL1, is a rare, provisional entity in the WHO 2016 classification and is considered a high‐risk disease according to the European LeukemiaNet 2017 risk stratification. We here present a retrospective, population‐based study of this disease entity from the Swedish Acute Leukemia Registry. By strict clinical inclusion criteria we aimed to identify genetic markers further distinguishing AML with t(9;22) as a separate entity. Twenty‐five patients were identified and next‐generation sequencing using a 54‐gene panel was performed in 21 cases. Interestingly, no mutations were found in NPM1, FLT3, or DNMT3A, three frequently mutated genes in AML. Instead, RUNX1 was the most commonly mutated gene, with aberrations present in 38% of the cases compared to around 10% in de novo AML. Additional mutations were identified in genes involved in RNA splicing (SRSF2, SF3B1) and chromatin regulation (ASXL1, STAG2, BCOR, BCORL1). Less frequently, mutations were found in IDH2, NRAS, TET2, and TP53. The mutational landscape exhibited a similar pattern as recently described in patients with chronic myeloid leukemia (CML) in myeloid blast crisis (BC). Despite the concomitant presence of BCR‐ABL1 and RUNX1 mutations in our cohort, both features of high‐risk AML, the RUNX1‐mutated cases showed a superior overall survival compared to RUNX1 wildtype cases. Our results suggest that the molecular characteristics of AML with t(9;22)/BCR‐ABL1 and CML in myeloid BC are similar and do not support a distinction of the two disease entities based on their underlying molecular alterations.